Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies
that address the underlying causes of heart disease, is sponsoring a study to better understand pediatric cardiomyopathy due to the MYBPC3 mutation.
The MyClimb Natural History Study is designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents <18 years of age with the MYBPC3 genetic mutation. Please CLICK HERE for more information and who to contact if you are interested in having your child participate.